- Home
- LEGH vs AUTL Comparison
LEGH vs AUTL Comparison
Compare LEGH & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- AUTL
- Stock Information
- Founded
- LEGH 2005
- AUTL 2014
- Country
- LEGH United States
- AUTL United Kingdom
- Employees
- LEGH N/A
- AUTL 463
- Industry
- LEGH Homebuilding
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGH Consumer Discretionary
- AUTL Health Care
- Exchange
- LEGH Nasdaq
- AUTL Nasdaq
- Market Cap
- LEGH 601.1M
- AUTL 590.8M
- IPO Year
- LEGH 2018
- AUTL 2018
- Fundamental
- Price
- LEGH $25.02
- AUTL $2.22
- Analyst Decision
- LEGH Buy
- AUTL Strong Buy
- Analyst Count
- LEGH 2
- AUTL 3
- Target Price
- LEGH $29.00
- AUTL $10.20
- AVG Volume (30 Days)
- LEGH 74.9K
- AUTL 1.4M
- Earning Date
- LEGH 03-14-2025
- AUTL 03-13-2025
- Dividend Yield
- LEGH N/A
- AUTL N/A
- EPS Growth
- LEGH N/A
- AUTL N/A
- EPS
- LEGH 2.18
- AUTL N/A
- Revenue
- LEGH $163,718,000.00
- AUTL $10,091,000.00
- Revenue This Year
- LEGH N/A
- AUTL $851.83
- Revenue Next Year
- LEGH $8.19
- AUTL $264.18
- P/E Ratio
- LEGH $11.51
- AUTL N/A
- Revenue Growth
- LEGH N/A
- AUTL 82.71
- 52 Week Low
- LEGH $19.42
- AUTL $2.07
- 52 Week High
- LEGH $29.31
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- LEGH 56.88
- AUTL 38.18
- Support Level
- LEGH $24.12
- AUTL $2.18
- Resistance Level
- LEGH $24.98
- AUTL $2.38
- Average True Range (ATR)
- LEGH 0.65
- AUTL 0.16
- MACD
- LEGH 0.18
- AUTL 0.01
- Stochastic Oscillator
- LEGH 90.07
- AUTL 7.94
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.